决定异体 CAR T 细胞排斥与扩增的细胞和分子机制
Cellular and molecular mechanisms determining allogeneic CAR T cell rejection and expansion.
我们评估了11例接受单一批次cemacabtagene ansegedleucel(cema-cel)治疗的大B细胞淋巴瘤患者,cemacabtagene ansegedleucel是一种异体抗CD19 CAR T产品。
英文原题:Exosomes derived from human umbilical cord mesenchymal stem cells attenuate hepatic ischaemia-reperfusion injury via the let-7i-5p/Faslg axis.
我们的研究结果表明,hucMSC-exos 通过抑制细胞凋亡减轻 HIRI。
背景:肝缺血再灌注损伤(HIRI)是肝移植中不可避免的过程,细胞凋亡在其中发挥关键作用。人脐带间充质干细胞来源外泌体(hucMSC-exo)是一种无细胞治疗手段,已受到广泛关注,有望减轻HIRI。但其抑制细胞凋亡的潜力及相关机制仍知之甚少。 目的:探究hucMSC-exo对HIRI后细胞凋亡的影响及潜在机制。 方法:研究hucMSC-exo对HIRI及L02细胞缺氧/复氧损伤的治疗效果。采用RNA测序检测hucMSC-exo处理后L02细胞差异表达基因,并分析凋亡标志物表达。通过microRNA(miRNA)测序分析hucMSC-exo及其处理后L02细胞中的miRNA表达谱。结合miRNA-mRNA分析鉴定候选miRNA及其调控靶基因,随后研究候选miRNA在小鼠HIRI和L02细胞缺氧/复氧损伤中的作用。 结果:荧光共聚焦显微镜显示,hucMSC-exo可有效归巢至肝脏并被肝细胞摄取,这可能与hucMSC-exo表面存在抗极晚期抗原4和抗淋巴细胞功能相关抗原1有关。hucMSC-exo通过抑制凋亡减轻肝细胞损伤。具体而言,hucMSC-exo中的let-7i-5p可抑制L02细胞中凋亡相关因子配体蛋白表达,导致B细胞淋巴瘤2(BCL-2)上调、BCL-2相关X蛋白和半胱天冬酶3下调,从而抑制L02细胞凋亡并增强细胞增殖活性。过表达let-7i-5p可在体内外有效增强hucMSC-exo的抗凋亡作用。 结论:我们的研究表明,hucMSC-exo通过抑制细胞凋亡减轻HIRI。我们证明hucMSC-exo靶向L02细胞凋亡,并通过let-7i-5p/凋亡相关因子配体通路发挥作用,从而改善HIRI。本研究加深了对hucMSC-exo调节肝细胞凋亡作用的认识,并凸显其作为HIRI治疗策略的潜力。
BACKGROUND: Hepatic ischaemia-reperfusion injury (HIRI) is an unavoidable process in liver transplantation, where apoptosis plays a critical role. Human umbilical cord mesenchymal stem cell-derived exosomes (hucMSC-exos), which constitute a cell-free therapeutic approach, have garnered extensive attention in alleviating HIRI. However, the potential of hucMSC-exos in mitigating apoptosis and their underlying mechanisms remain largely unknown. AIM: To investigate the effects of hucMSC-exos on apoptosis after HIRI and explore the underlying mechanisms. METHODS: The therapeutic effects of hucMSC-exos on HIRI and hypoxia/reoxygenation injury in L02 cells were investigated. RNA sequencing was used to detect differentially expressed genes in L02 cells after hucMSC-exo treatment, and the expression of apoptosis markers in L02 cells was analyzed. MicroRNA (miRNA) sequencing was performed to analyse the miRNA expression profiles of hucMSC-exos and L02 cells after hucMSC-exo treatment. Through a miRNA-mRNA integrated analysis, candidate miRNAs and their regulated target genes were identified. We subsequently studied the roles of these candidate miRNAs in mouse HIRI and L02 cell hypoxia/reoxygenation injury. RESULTS: Fluorescence confocal microscopy revealed that hucMSC-exos effectively homed to the liver and were taken up by hepatocytes, likely due to the presence of anti-very late antigen-4 and anti-lymphocyte function-associated antigen-1 on the surface of hucMSC-exos. HucMSC-exos alleviate hepatocyte damage by inhibiting apoptosis. Specifically, let-7i-5p within hucMSC-exos inhibited the expression of the factor-related apoptosis ligand protein in L02 cells, leading to the upregulation of B-cell lymphoma-2 and the downregulation of B-cell lymphoma-2-associated X protein and cysteinyl aspartate specific proteinase-3, thereby inhibiting L02 cell apoptosis and enhancing cell proliferation activity. The overexpression of let-7i-5p effectively enhanced the antiapoptotic effects of hucMSC-exos both in vitro and in vivo . CONCLUSION: Our findings indicate that hucMSC-exos alleviate HIRI by inhibiting apoptosis. We demonstrated that hucMSC-exos target apoptosis in L02 cells and mediate the let-7i-5p/factor-related apoptosis ligand pathway, thereby ameliorating HIRI. This study provides new insights into the role of hucMSC-exos in hepatocyte apoptosis and highlights the potential of hucMSC-exos as a therapeutic strategy for HIRI.
MEMBER ACCOUNT
登录成功会直接打开下一页。